FLOT2 overexpression is associated with the progression and prognosis of human colorectal cancer

Figures

• 

  Figure 1.. Expression of FLOT2 is upregulated in colorectal cancer cell lines. (A) The normal colon cell (FHC) and colorectal cancer cell lines (HT-29, SW480, Lovo, SW1116, SW620, Colo205 and DLD1) were analyzed by western blotting. GAPDH served as a loading control. (B) FLOT2 mRNA expression in the various cell lines was quantified using the reverse transcription-quantitative polymerase chain reaction. Expression level were normalized to GAPDH and presented as the mean ± standard error of the mean. *P<0.05 vs. FHC. FLOT2, flotillin-2.

• 

  Figure 2.. Expression of FLOT2 is increased in colorectal cancer tissues. (A) Tissues were analyzed by western blotting. GAPDH served as a loading control. (B) Mean T/N ratios of FLOT2 mRNA expression were determined following quantification using the reverse transcription-quantitative polymerase chain reaction. Results are expressed as the mean ± standard error of the mean. T, tumor tissues; N, adjacent non-tumor tissues.

• 

  Figure 3.. Colorectal cancer tissues exhibit increased FLOT2 expression, as revealed by immunohistochemistry. FLOT2 stained brown, with weaker expression staining yellow. FLOT2, flotillin-2; T, tumor tissues; N, adjacent non-tumor tissues.

• 

  Figure 4.. FLOT2 expression is association with the survival rate of patients with colorectal cancer. (A) OS and (B) 5-year DFS rates for cases with high FLOT2 expression compared with those for cases with low FLOT2 expression for all patients. (C) OS rate for cases with high FLOT2 expression compared with cases with low FLOT2 expression for patients with pT1-2 grade tumors. (D) OS rate for cases with high FLOT2 expression compared with that for cases with low FLOT2 expression for patients with pT3-4 grade tumors. (E) OS rate for cases at early clinical stages (AJCC stage I–II) with high FLOT2 expression compared with those for cases with low FLOT2 expression levels. (F) OS rate for cases at late stages (AJCC stage III–IV) with high FLOT2 expression levels compared with those for cases with low FLOT2 expression. FLOT2, flotillin-2; OS, overall survival; DFS, disease-free survival.